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Abstract
Introduction: The purpose of this study was to replicate genetic factors associated with the susceptibility to
Behçet’s disease (BD). We conducted a two-stage candidate genes association and functional study, involving 477
BD patients and 1,334 normal controls of Chinese Han descent.
Methods: The genotyping of five candidate genes/loci, including LOC100129342, KIAA1529, CPVL, UBASH3B and
UBAC2, were performed using TaqMan single nucleotide polymorphism (SNP) assays. Real-time PCR and luciferase
reporter assay were performed to test the function of the identified promoter polymorphism. The main outcome
measures were genotype frequencies and expression levels in BD patients.
Results: The first-stage study results showed that UBAC2 (rs9513584, Pc = 0.018, OR = 1.4), but not LOC100129342,
KIAA1529, CPVL, UBASH3B was associated with the susceptibility to BD in Chinese Han. The fine-mapping association
study of UBAC2 identified six risk SNPs for BD in the Chinese cohort; three of them were verified in validation study
(rs3825427, first-stage Pc = 2.2 × 10-3, second-stage Pc = 9.3 × 10-3, combined Pc = 6.9 × 10-6; rs9517668, first-stage
Pc = 1.7 × 10-3, second-stage Pc = 0.03, combined Pc = 3.3 × 10-4; rs9517701, first-stage Pc = 5.1 × 10-3, second-
stage Pc = 9.0 × 10-3, combined Pc = 2.9 × 10-5; respectively). Functional analysis showed that the risk T allele of
the promoter polymorphism rs3825427 had a significantly lower promoter activity than the non-risk G allele (P =
0.002) and a decreased expression of UBAC2 transcript variant 1 in peripheral blood mononuclear cells (PBMCs) and
skin of normal controls carrying the risk T allele than that in individuals with the G allele (P = 0.045, P = 0.025;
respectively). The mRNA expression of UBAC2 transcript variant 1 was significantly decreased in PBMCs and skin of
BD patients as compared with controls (P = 0.025; P = 0.047, respectively). The mRNA expression of UBAC2
transcript variant 2 was significantly increased in skin of BD patients as compared with controls (P = 0.004).
Conclusions: This study replicates a predisposition gene to BD, UBAC2, and suggests that UBAC2 may be involved
in the development of BD through its transcriptional modulation.
Introduction
Behçet’s disease (BD) is generally considered as a refrac-
tory multisystem disorder characterized by recurrent
oral ulceration, genital ulceration, recurrent uveitis and
multiple skin lesions [1,2]. BD presents a significant geo-
graphical distribution, mainly seen in the countries
along the ancient silk route [3]. It is one of the most
common and severe sight-threatening uveitis entities in
China [3]. Although the etiology of this disease remains
unclear, it is currently thought that a genetic predisposi-
tion coupled with a triggering event seems to lead to its
development. Although HLA-B51 has been found to be
strongly associated with BD [4-7], it is estimated that
HLA-B51 only accounts for 20% of the risk genes for
this disease [8]. A whole genome linkage study has
implicated several potential non-HLA contributory loci/
genes for BD [9]. Candidate gene association studies
have identified a number of susceptible genes for BD,
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including IL23R [10], CTLA4 [11], eNOS [12], SUMO4
[13,14], NOD2 [15], IL1A [16], manganese superoxide
dismutase (SOD) [17] and so on. These studies tremen-
dously enhanced our understanding of the genetic etiol-
ogy of BD. However, these identified risk genes only
contribute to about 30% of the predisposition for BD
[18].
Fei and coworkers [19] conducted a genome-wide
association study (GWAS) on 152 Turkish Behçet’s dis-
ease patients using the DNA pooling approach and
reported the association of BD with five novel loci/
genes, including LOC100129342, KIAA1529, CPVL,
UBASH3B and ubiquitin-associated domain containing 2
(UBAC2), among which the genetic association between
UBAC2 and BD was lately confirmed and functional sig-
nificance was tested by the same study group [20]. As
far as we know, the association result needs to be con-
firmed by further replication studies, particularly in
other ethnic groups. We, therefore, conducted a candi-
date association to investigate the association between
the identified risk genes/loci and BD in the non-Turkish
ethnic population. Our result revealed that UBAC2 was
associated with BD in Han Chinese. Fine mapping and
validation studies further confirmed UBAC2 as suscept-
ibility gene for Behçet’s disease. Further functional study
showed that the risk T allele of rs3825427 in UBAC2
was associated with the decreased promoter activity and
its mRNA expression. These genetic associations and




Written informed consent was obtained from each parti-
cipant, and this study was approved by the Clinical
Research Ethics Committee of the First Affiliated Hospi-
tal of Chongqing Medical University and Zhongshan
Ophthalmic Center, Sun Yat-sen University (Permit
Number: 2009-201004).
Subjects
One hundred forty-seven BD patients and 951 normal
controls enrolled in the first-stage were recruited from
April 2005 to March 2008 in Southern China at
Zhongshan Ophthalmic Center, Sun Yat-sen University.
The replication cohort is comprised of 330 Han Chinese
BD patients and 383 Han Chinese normal controls,
which were recruited from April 2008 to March 2010 in
Western China at the First Affiliated Hospital of
Chongqing Medical University (Table 1). The diagnosis
of BD was based on the criteria of the International
Study Group for BD [2]. Twelve patients with typical
nongranulomatous uveitis, multiform skin lesions or
genital ulcers in association with arthritis or other clini-
cal features, were diagnosed as having BD according to
the criteria of the Behçet’s Disease Research Committee
of Japan and were also included in this study (Table 2)
[21]. The control populations consisted of unrelated
healthy individuals from the same geographical regions
as the BD patients and were age, sex and ethnically
matched with the patients.
SNPs selection
We chose the enrolled 25 SNPs based on the following
principle: we focused on the UBAC2 gene and ran Hap-
loview software (Daly Lab at the Broad Institute, Cam-
bridge, MA, USA) using Chinese Han Beijing data to
screen out tagSNPs including rs3825427, rs1927726,
rs9517668, rs9554581, rs4636771, rs7332161, rs9517701,
rs7325747, rs912129, rs4772190 and also included the
reported BD associated SNP rs9513584 [19]. In order to
enhance the accuracy rating of genotyping, we also
included 16 SNPs with high heterozygosity (allele fre-
quency > 0.1).
The three SNPs, including rs3825427, rs9517668 and
rs9517701, were enrolled in the replication study
because of their smaller Bonferroni corrected P-value.
The call rate of SNP rs9517699 did not meet the quality
standard in the replication study (call rate < 0.80), so
SNP rs9517699 was excluded in the replication analysis
(Additional file 1).
SNP genotyping
Genomic DNA was extracted from the peripheral blood
of patients and controls using the QIAamp DNA Blood
Mini Kit (QIAGEN Inc., Hilden, Germany) according to
the manufacturer’s instructions. The Genotyping was
determined by TaqMan® SNP Genotyping Assays
Table 1 Summary characteristic of Behçet’s patients and normal control subjects in this study
Case Control







Stage I 147 32.90 ± 7.50 129/18 951 39.77 ± 9.99 712/239
Stage II 330 33.39 ± 7.98 268/62 383 34.61 ± 7.85 301/82
Combined 477 33.07 ± 7.64 397/80 1334 37.07 ± 9.11 1,013/321
SD, standard deviation
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(Applied Biosystems, Foster City, CA, USA) on the
Applied Biosystems 7500 Real-Time PCR System
according to the manufacturer’s instructions. All SNPs
tested in this study had a genotyping success rate > 98%
and accuracy > 99% as judged by random re-sequencing
of 20% of samples in all subjects.
Real-time quantitative PCR analysis
Anticoagulated blood samples were obtained using
vacuum tubes with EDTA. PBMCs were prepared from
venous blood of BD patients (n = 8) and normal con-
trols (n = 52) by Ficoll-Hypaque density-gradient cen-
trifugation. Skin was obtained from the skin lesions of
patients (n = 4) and the scrotum of normal controls (n
= 22). Total RNA was isolated from skin and PBMCs
of the patients or controls by using the QIAamp®
RNA Blood Mini kit (QIAGEN Inc., Hilden, Germany)
or Qiagen RNeasy Fibrous Tissue Mini Kit (QIAGEN
Inc., Hilden, Germany) with treatment of Dnase I,
according to the manufacturer’s instructions and
reversed into cDNA according to the Superscript pro-
tocol (SuperScript III First-Strand Synthesize System,
Invitrogen, Carlsbad, CA, USA). To compare the
mRNA expression of the two protein-coding transcript
variants of UBAC2, Real-time Quantitative PCR was
performed using the Applied Biosystems 7500 System
(Applied Biosystems) with the following primers
(UBAC2F:5’CCG GCT CCA GTG GGC TCT ACA3’/
UBAC2R:5’GGG CGA GCA GGA GGG AGA GG3’)
for the UBAC2 transcript variant 1 to generate a 81 bp
product and (UBAC2F: 5 ’TAGGAAGTCGTGGC-
GAGGGAGC3’/UBAC2R: 5’GCCTTGTCTGCTGAC
CACCGCT3’) for the UBAC2 transcript variant 2 to
generate a 84 bp product. The b-actin (b-actinF:
5’GGA TGC AGA AGG AGA TCA CTG3 ’/b-
actinR:5’CGA TCC ACA CGG AGT ACT TG3’) was
chosen as the internal reference gene to normalize
UBAC2 expression. RT-PCR conditions were one cycle
of 95°C for 10 minutes, followed by 40 cycles in which
each cycle included 95°C for 15 sec, 60°C for 1 minute,
and 95°C for 15 sec, 60°C for 1 minute, 95°C for 15
sec, 60°C for 15 sec.
Luciferase Reporter Assay
The whole genome synthesized promoter sequences of
UBAC2 carrying the T allele or the G allele of SNP
rs3825427 were cloned into pGL3-basic vector (Pro-
mega, Madison, WI, USA). This vector was then transi-
ently transfected into HEK293 cells. Reporter plasmid
was transfected to cells using Lipofectamine reagent
(Life Technologies, Grand Island, NY, USA). Transfec-
tion efficiency was standardized by cotransfecting with
pRL-SV40 (Promega). Luciferase activity was determined
after 24 hours incubation using a Luciferase Assay sys-
tem (Beyotime, Jiangsu, China). For each plasmid con-
struct, three independent transfection experiments were
performed, and each was done in triplicate.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was tested using
the chi-square test and no SNPs showed significant
deviation from HWE (P >0.05). Odds ratios (OR) and
95% confidence intervals (95% CI) were calculated by
using using SPSS version 17.0 (Chicago, IL, USA) to
estimate disease risk. Linkage disequilibrium (LD) was
examined by using Haploview (version 4.2, Daly Lab at
the Broad Institute, Cambridge, MA, USA). To account
for multiple testing, the Bonferroni correction was
applied. Review Manager 4.2 (Cochrane Collaboration,
Oxford, UK) was used to perform meta-analysis. The
conditional logistic regression analysis (SAS, 9.13, Cary,
NC, USA) was performed to localize the effect and iden-
tify the number of independent effects.
Results
The clinical findings of the BD patients included in our
study are shown in Table 2. No statistical difference in
the distribution of age and gender was observed
between BD patients and controls (P >0.05).
The identification of risk gene for BD by candidate genes
association study in Southern China (first-stage study)
Five genes/loci, that is, LOC100129342, KIAA1529,
CPVL, UBASH3B and UBAC2, have been identified as
risk factors for BD in Turkish. These five candidate
genes/loci were not validated by other ethnic popula-
tions. We conducted a candidate gene association study
to confirm the association result using 147 BD patients
and 951 controls. Our results showed that the
rs9513584 polymorphism inUBAC2 was associated with
the susceptibility to BD (Pc = 0.018, OR = 1.4, meta-
analysis OR = 1.5) (Table 3). There was no association
of LOC100129342, KIAA1529, CPVL and UBASH3B
with BD in the Chinese cohorts (Table 3).
Table 2 The clinical characteristics of Behcet patients
Characteristics BD Patients




Oral ulcer 465 97.5
Genital ulcer 167 35.0
Hypopyon 111 23.3
Skin lesions 270 56.6
Positive pathergy test 167 35.0
Arthritis 135 28.3
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Fine-mapping study and validation study of UBAC2
association in Chinese cohort
The variant in UBAC2 showed a consistent association
in the Turkish and Chinese cohort, therefore, UBAC2
was considered as the most important candidate among
the five loci. We, therefore, fine-mapped the UBAC2
using 25 SNPs and found that 6 SNPs, that is,
rs3825427, rs1927726, rs9517668, rs9554581, rs9517701
and rs9517699, were associated with BD (P ≤0.05/25 =
0.002) (Table 4, Figure 1 and Additional file 1). We next
checked the independence of the evidence for multiple
associations within the UBAC2 locus by carrying out a
conditional logistic regression analysis of the 25 SNPs in
UBAC2. After control for the genetic effect of
rs3825427, none of the 24 SNPs remained significantly
associated with Behçet’s disease after correction for the
number of SNPs tested by the conditional analysis (the
smallest P = 0.0024 > 0.05/25 = 0.002). Therefore, the
multiple associations within the UBAC2 locus are not
independent.
To further validate the fine-mapping result, we per-
formed a replication study on the selected three SNPs,
including rs3825427, rs9517668 and rs9517701, using
the West-Southern China cohort. The result showed
that all of the three selected SNPs were associated with
BD (rs3825427, First-stage Pc = 2.2 × 10-3, OR = 1.5,
Second-stage Pc = 9.3 × 10-3, OR = 1.4, combined Pc =
6.9 × 10-6, OR = 1.5; rs9517668, First-stage Pc = 1.7 ×
10-3, OR = 1.6, Second-stage Pc = 0.03, OR = 1.3, com-
bined Pc = 3.3 × 10-4, OR = 1.4; rs9517701, First-stage
Pc = 5.1 × 10-3, OR = 1.5, Second-stage Pc = 9.0 × 10-3,
OR = 1.4, combined Pc = 2.9 × 10-5, OR = 1.4; respec-
tively) (Table 4).
Effects of promoter polymorphism of rs3825427 on
UBAC2 transcriptional level
Since the rs3825427 polymorphism is located in the
promoter region of UBAC2 and bioinformatics analysis
revealed that this G/T SNP changed the binding site for
transcriptional factors, we performed a series of
Table 3 The meta- analysis result combined our data and Turkish data
SNP Nearest gene Risk allele Population N Risk allele frequency P-value Pc value OR (95% CI)
Cases Controls Cases Controls
rs11206377 LOC100129342 G Turkisha 152 170 66.1 51.4 3.0 × 10-4 1.5 × 10-3 1.8 (1.3 to 2.6)
(1p34) Chinese 147 951 56.5 53.9 0.410 NS 1.1 (0.9 to 1.4)
meta-analysis 1.3 (1.1 to 1.6)
rs2061634 KIAA1529 G Turkish 152 170 42.7 26.7 4.2 × 10-5 2.1 × 10-4 2.0 (1.5 to 2.9)
(9q22) Chinese 147 951 79.9 80.0 0.971 NS 1.0 (0.7 to 1.4)
meta-analysis 1.4 (1.1 to 1.7)
rs317711 CPVL C Turkish 152 170 25.5 13.2 1.0 × 10-4 5.0 × 10-4 2.2 (1.4 to 3.3)
(7p15-p14) Chinese 147 951 85.8 84.1 0.739 NS 1.3 (0.9 to 1.9)
meta-analysis 1.6 (1.2 to 2.1)
rs4936742 UBASH3B T Turkish 152 170 56.7 43.4 1.5 × 10-3 7.5 × 10-3 1.7 (1.2 to 2.4)
(11q24) Chinese 147 951 61.5 63.2 0.590 NS 0.9 (0.7 to 1.2)
meta-analysis 1.2 (0.9 to 1.4)
rs9513584 UBAC2 G Turkish 152 170 44.4 33.2 5.8 × 10-3 0.029 1.6 (1.2 to 2.3)
(13q32) Chinese 147 951 51.4 42.3 3.6 × 10-3 0.018 1.4 (1.1 to 1.8)
meta-analysis 1.5(1.2 to 1.8)
aData from reference 19; OR (95% CI), Odds ratio (95%CI); NS: not significant; Pc: Bonferroni corrected P-value
Table 4 Summary of the association of UBAC2 SNPs with Behcet’s disease in Han Chinese population
First-stage Second-stage Combined study
SNPs MA AF Pc
Value
OR 95% CI AF Pc OR 95% CI AF Pc OR 95% CI







































































95% CI, confidence interval; AF, allele frequency; MA, minor allele; OR, odds ratio; Pc: Bonferroni corrected P-value.
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functional analyses to examine whether rs3825427 poly-
morphism affected the expression of UBAC2. We tested
two protein-coding transcript variants of UBAC2 in
mRNA level with the presence of different genotype
(TT/GT/GG) in rs3825427. The mRNA level of UBAC2
transcript variant 1 was found decreased in PBMCs and
the skin of normal individuals with the TT genotype
compared with those with the GG genotype (Bonferroni
corrected P = 0.045, P = 0.025; respectively) (Figure 2).
No significant difference was observed in the expression
of UBAC2 transcript variant 2 between the various gen-
otypes (Figure 2).
We subsequently performed a Dual Luciferase Repor-
ter Gene Assay to evaluate whether the promoter
sequence carrying different alleles have different promo-
ter activity. The promoter sequences of UBAC2 carrying
T allele or G allele of SNP rs3825427 were synthesized
by Sangon Biotech (Shanghai, P.R. China). Sequencing
was performed to validate the result of synthesis and the
result showed that only one variant was observed in the
location of the rs3825427 polymorphism. The luciferase
reporter expression was found to be decreased in the T
allele as compared to cells carrying the G allele (P =
0.002) (Figure 3).
Down-regulated expression of UBAC2 in PBMCs and skin
of BD patients
A further study was performed to test whether the
mRNA expression of UBAC2 was altered in BD. The
results showed that the expression of UBAC2 was signif-
icantly decreased in the PBMCs and skin from BD
patients as compared with that observed in normal
controls (P = 0.025, P = 0.047; respectively) (Figure 4).
The mRNA expression of UBAC2 transcript variant 2
was significantly increased in skin of BD patients as
compared with controls (P = 0.004) (Figure 4).
Discussion
In this study we performed a candidate gene analysis
combined with a fine mapping study and the result
showed a link of several SNPs in the UBAC2 gene with
the susceptibility to Behçet’s disease in Chinese Han
patients. Functional analysis revealed that the risk-asso-
ciated T allele of rs3825427 significantly down-regulated
the expression of UBAC2 mRNA. A significantly
decreased expression of UBAC2 was observed in
PBMCs and skin of BD patients compared to normal
controls. Our study confirms the association between a
single SNP rs9513584 of the UBAC2 gene and BD,
which was recently reported in a group of Turkish BD
patients. Of interest was the observation that the G
allele of rs9513584 was associated with the absence of
eye disease in the study in Turkish patients. We could
not address this observation since all our patients had
eye disease.
The UBAC2 gene, also known as PHGDHL1, is
located at 13q32.3. The UBAC2 gene encodes an ubiqui-
tination related structural domain. The study reported
by Fei et al. [19] and their subsequent replication
showed the association of UBAC2 gene with Behçet’s
disease and revealed the possible contribution of
UBAC2 in the pathogenesis of BD [20]. Our present
study successfully replicated the association between
Figure 1 Genetic association analysis in UBAC2 gene region.
Overview of SNPs across the UBAC2 gene region in the Chinese
cohort. Linkage disequilibrium (r2) to the most significantly SNP
(rs9517668, red diamond) is color-coded (red: r2 > 0.8; orange: r2 =
0.5-0.8; yellow: r2 = 0.2-0.5; white: r2 < 0.2). Recombination rates
across each region in HapMap CHB are shown in light blue (right y
axis). The chromosomal locations and relative positions of genes
according to hg18 are shown (x axis).
Figure 2 Comparison of UBAC2 variants transcriptional level
among different genotypes of rs3825427. Five GG genotype,
four GT genotype, three TT genotype PBMCs samples and four GG
genotype, three GT genotype and five TT genotype skin samples
were used to examine the expression of UBAC2 transcript variant 1
and 2 and each sample were assayed three times. The mean ± SD
is given for each genotype from three experiments. Statistical
significance was taken when Bonferroni corrected two-tailed P <
0.05 using SPSS17.0.
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UBAC2 and BD in a Chinese cohort. Two other GWAS
did not identify the UBAC2 gene as the risk gene for
Behçet’s disease [22,23]. The inconsistent result may be
partly explained by the population heterogeneity and the
disparate SNP array (Affymetrix SNP array, Santa Clara,
CA, USA vs Illumina SNP array, San Diego, CA, USA).
In a previous study, we also identified a polymorphism
in a ubiquitin-related gene, SUMO4, that was associated
with the susceptibility to Behçet’s disease in a Chinese
Han population [13]. Another ubiquitination related
gene, UBE2QL1, was also found to be associated with
BD in a Turkish cohort [23]. Previous studies suggest
that ubiquitination reactions are involved in the regula-
tion of receptor tyrosine kinase signaling and may play
important roles in the TNF-a, IL-1b, and TCR-mediated
NF-B activation pathway [24,25]. NF-B has been
demonstrated to play a crucial role in the pathogenesis
of BD through regulating the apoptosis-related factors
and increasing the resistance of T cells to apoptosis
[26]. All these findings indicate that the ubiquitination-
related pathway may have a protective effect in the
development of Behçet’s disease.
SNP rs3825427 in the UBAC2 gene encodes a promo-
ter polymorphism. Our study showed a close association
of this SNP with the susceptibility to BD. To determine
whether the promoter polymorphism may modulate the
expression of this gene, dual luciferase reporter gene
assays and real-time PCR analysis were performed and
the results showed that the T allele was associated with
decreased promoter activity and may down-regulate the
expression of UBAC2. These findings suggest that the
rs3825427 polymorphism may lead to the down-regula-
tion of UBAC2 expression. More interestingly, UBAC2
transcription was found to be down-regulated in PBMCs
and skin of BD patients as compared to controls. Our
results are consistent with that observed in mice defi-
cient in the homologous UBA domain as reported by
Carpino et al. [27] They found that UBA knockout mice
showed increased cytokine production and also exhib-
ited an increased incidence and severity of experimental
autoimmune encephalomyelitis (EAE) as compared with
wild-type mice [27].
Several possible limitations of the present study merit
particular consideration. First, the patients enrolled in
our study were recruited from the Eye Department.
Because BD usually affects multiple systems, the patients
enrolled in this study might, therefore, represent a sepa-
rate disease population. Second, the patients enrolled in
the replication study were recruited only from Chinese
Han individuals and the sample size is relatively small.
The results presented here need to be confirmed in
other ethnic populations and using larger samples.
Finally, although molecular biology study provides func-
tional evidence for the rs3825427 polymorphism, this
result is generally suggestive and does not exactly
explain how the genetic variant translates into physiolo-
gic processes and then affects disease susceptibility.
Therefore, the association results presented here should
Figure 4 Real-time RT-PCR analysis of UBAC2 transcript variant
1 and 2 mRNA levels between Behçet’s patients and normal
controls. UBAC2 transcript variant 1 and 2 mRNA levels derived
from PBMCs of 23 normal controls and 6 patients or from skin of 9
normal controls and 4 patients. Each RT-PCR was assayed in
triplicate. Significance was examined by using SPSS’s independent
sample t test.
Figure 3 Effects of the rs3825427 genotype in UBAC2 on
luciferase activity in cultured HEK 293 cells. pGL3 luciferase
reporter recombinant plasmids containing an UBAC2 promoter
sequence with the risk allele T or wild-type G allele at SNP
rs3825427 were transfected into HEK293 cells. Renilla luciferase
plasmid pTK-SV40 was cotransfected with each construct as an
internal control for normalization. The mean ± SD is given for each
construct from three experiments. Statistical significance was taken
when two-tailed P < 0.05 using SPSS17.0 independent sample t test.
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be investigated further using more functional
experiments.
Conclusion
In conclusion, our study replicated the association of
UBAC2 with BD and identified a promoter SNP of
UBAC2, rs3825427, to be associated with the increased
risk for BD in Chinese. The functional study showed
that this SNP may be involved in the development of
BD through transcriptional modulation of UBAC2.
Additional material
Additional file 1: The association of UBAC2 gene with Behcet’s
disease and linkage disequilibrium of UBAC2 gene. Table S1
presented the association analysis of three SNPs in UBAC2 gene with
Behcet’s disease in Han Chinese population. Figure S1 showed linkage
disequilibrium plots of UBAC2 gene based on the HapMap Phase II
dataset for the Han Chinese from the Beijing population by Haploview
4.2 software.
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